



# XXVIII IACRLRD Symposium

International Association for Comparative Research on Leukemia and Related Diseases

XXVIII IACRLRD SYMPOSIUM • MD ANDERSON CANCER CENTER • HOUSTON, TEXAS, USA • OCT 30-NOV 1, 2017

## Monday, October 30, 2017

Start	End	Time	Topic	Speaker
8:00 AM	8:15 AM	0:15	Welcome and Introduction	Hagop Kantarjian (Houston)
8:15 AM	9:55 AM	1:40	<b>Infections, Inflammation and Cancer</b>	
			<i>Session Chairs: Ali Bazarbachi / Luigi Chieco Bianchi</i>	
8:15 AM	8:35 AM	0:20	HIV-Associated Lymphomas	Joseph Alvarnas (Duarte)
8:35 AM	8:55 AM	0:20	HTLV-I Associated Adult T-Cell Leukemia/Lymphoma	Ali Bazarbachi (Beirut)
8:55 AM	9:15 AM	0:20	Viral and Cellular Factors that Contribute to HTLV-1 Persistence	Genoveffa Franchini (Bethesda)
9:15 AM	9:35 AM	0:20	Development of New Methods to Treat EBV-Associated Lymphoma	Paul Lieberman (Philadelphia)
9:35 AM	9:55 AM	0:20	Hepatitis C-Associated Lymphomas	Olivier Hermine (Paris)
9:55 AM	10:25 AM	0:30	<b>Break</b>	
10:25 AM	1:05 PM	2:40	<b>Acute Myeloid Leukemia</b>	
			<i>Session Chairs: Jerzy Holowiecki / Clara Bloomfield</i>	
10:25 AM	10:45 AM	0:20	How I Treat AML	Jerzy Holowiecki (Katowice)
10:45 AM	11:05 AM	0:20	FLT3 Molecular Mutations and Treatment Approaches	Richard Stone (Boston)
11:05 AM	11:25 AM	0:20	Targeted Therapy of IDH1/IDH2 Mutated AML	Eytan Stein (New York)
11:25 AM	11:45 AM	0:20	IDH Mutant Inhibitors: Clinical Progress & Future Directions	Eyal Attar (Cambridge)
11:45 AM	12:05 PM	0:20	Venetoclax and BCL2 Inhibition in AML	Marina Konopleva (Houston)
12:05 PM	12:25 PM	0:20	The Promise of Toxin Conjugated Monoclonal Antibodies	Harry Erba (Birmingham)
12:25 PM	12:45 PM	0:20	Targeting T-Cells to AML using Bispecific Antibodies	Marion Subklewe (Munich)
12:45 PM	1:05 PM	0:20	Current Management of Newly Diagnosed Acute Promyelocytic Leukemia	Francesco Lo Coco (Rome)
1:05 PM	2:05 PM	1:00	<b>Box Lunch: Meet the Professor Sessions [and World Committee Meeting 1]</b>	
1:05 PM	2:05 PM	1:00	MTP 1: AML	Bob Lowenberg (Rotterdam)
1:05 PM	2:05 PM	1:00	MTP 2: ALL	Renier Brentjens (New York)
1:05 PM	2:05 PM	1:00	MTP 3: FLT3 and IDH1/2 Inhibitors	Eytan Stein (New York)
2:05 PM	2:55 PM	0:50	<b>John Moloney Memorial Lecture</b>	
			<i>Session Chair: Gert Ossenkoppele</i>	
2:05 PM	2:10 PM	0:05	Introduction: John Moloney Memorial Lecture	Gert Ossenkoppele (Amsterdam)
2:10 PM	2:55 PM	0:45	State of the Art Therapy of AML: 2017	Bob Lowenberg (Rotterdam)
2:55 PM	3:55 PM	1:00	<b>Acute Lymphoblastic Leukemia</b>	
			<i>Session Chairs: Dieter Hoelzer / Hagop Kantarjian</i>	
2:55 PM	3:15 PM	0:20	How I Treat ALL	Dieter Hoelzer (Frankfurt)
3:15 PM	3:35 PM	0:20	CD19- and CD22-Targeted Therapies in ALL Salvage Therapy	Max Topp (Würzburg)
3:35 PM	3:55 PM	0:20	CAR T-Cells Targeting Tumor Antigens	Renier Brentjens (New York)
3:55 PM	4:25 PM	0:30	<b>Break</b>	
4:25 PM	5:15 PM	0:50	<b>Howard Temin Memorial Lecture</b>	
			<i>Session Chair: Daniela Krause</i>	
4:25 PM	4:30 PM	0:05	Introduction: Howard Temin Memorial Lecture	Daniela Krause (Frankfurt)
4:30 PM	5:15 PM	0:45	The Fulfillment & Future Promise of Monoclonal Antibodies in Frontline ALL	Hagop Kantarjian (Houston)
5:15 PM	5:45 PM	0:30	<b>Transport to Hotel</b>	

5:45 PM	7:45 PM	2:00	<b>Welcome Reception &amp; Opening Ceremony</b>	Houston Marriott Medical Center
5:45 PM	6:05 PM	0:20	Opening Ceremony and Presidential Address	Hagop Kantarjian (Houston)
			<b>First Place Award Winner</b>	
6:05 PM	6:15 PM	0:10	Oral Abstract CI-026: Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML)	Naval Daver (Houston)
			<b>Second Place Award Winner</b>	
6:15 PM	6:25 PM	0:10	Oral Abstract CML-020: Cytogenetic and molecular failure on 12month will be the optimal time point for BCR-ABL1 Tyrosine Kinase Domain mutation analysis in patients with chronic myeloid leukemia; The analysis based on 2013 European LeukemiaNet recommendation	Sung-Eun Lee (Seoul)
			<b>Third Place Award Winner</b>	
6:25 PM	6:35 PM	0:10	Oral Abstract AML-023: Randomized Phase II study of Guadecitabine (SGI-110) based regimens comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 + Ida), and 5 days + Cladribine (SGI5 + Clad), in previously untreated patients $\geq$ 70 years with Acute Myeloid Leukemia (AML) – a Bayesian design	Kiran Naqvi (Houston)
			<b>Fourth Place Award Winner</b>	
6:35 PM	6:45 PM	0:10	Oral Abstract CLL-009: Mutations of BRAF and BIRC3 identify a subgroup of chronic lymphocytic leukemia with very poor prognosis upon FCR treatment	Riccardo Moia (Novara)
6:45 PM	7:45 PM	1:00	<b>Cocktails and Poster Viewing</b>	Houston Marriott Medical Center
<b>Total</b>		<b>11:45</b>		

**Tuesday, October 31, 2017**

Start	End	Time	Topic	Speaker
8:00 AM	9:20 AM	1:20	<b>Myelodysplastic Syndromes</b>	
			<i>Session Chairs: Rami Komrokji / Guillermo Garcia-Manero</i>	
8:00 AM	8:20 AM	0:20	How I Treat MDS	Guillermo Garcia-Manero (Houston)
8:20 AM	8:40 AM	0:20	Molecular Targets and Therapeutic Potential	Rami Komrokji (Tampa)
8:40 AM	9:00 AM	0:20	Advances for Older, High-Risk MDS Patients	Michael Lübbert (Freiberg)
9:00 AM	9:20 AM	0:20	New MDS Treatments on the Horizon	Mikael Sekeres (Cleveland)
9:20 AM	10:10 AM	0:50	<b>Kenneth B McCredie Memorial Lecture</b>	
			<i>Session Chair: Emil J Freireich</i>	
9:20 AM	9:25 AM	0:05	Introduction: Kenneth B McCredie Memorial Lecture	Emil J Freireich (Houston)
9:25 AM	10:10 AM	0:45	Survival with CML in the TKI Era: Final Results of CML–Study IV	Rüdiger Hehlmann (Mannheim)
10:10 AM	10:40 AM	0:30	<b>Break</b>	
10:40 AM	11:40 AM	1:00	<b>Chronic Myeloid Leukemia</b>	
			<i>Session Chairs: Rüdiger Hehlmann / Richard Larson</i>	
10:40 AM	11:00 AM	0:20	Practical Monitoring of CML: When to Change Treatment	Giuseppe Saglio (Turin)
11:00 AM	11:20 AM	0:20	Role of Stem Cell Transplant in CML	Jerry Radich (Seattle)
11:20 AM	11:40 AM	0:20	Up and Coming Treatment Strategies in CML	Richard Larson (Chicago)
11:40 AM	12:40 PM	1:00	<b>Box Lunch: Meet the Professor Session [and World Committee Meeting 2]</b>	
11:40 AM	12:40 PM	1:00	MTP 4: CAR T-Cells	William Wierda (Houston)
11:40 AM	12:40 PM	1:00	MTP 5: CML	Jerry Radich (Seattle)
11:40 AM	12:40 PM	1:00	MTP 6: Monoclonal Antibodies in ALL, AML	Farhad Ravandi (Houston)
12:40 PM	2:00 PM	1:20	<b>Chronic Lymphocytic Leukemia</b>	
			<i>Session Chairs: Michael Keating / Jennifer R. Brown</i>	
12:40 PM	1:00 PM	0:20	How I Treat CLL	Michael Keating (Houston)
1:00 PM	1:20 PM	0:20	Ibrutinib and BTK Inhibitors	Susan O'Brien (Irvine)
1:20 PM	1:40 PM	0:20	PI3K Inhibitors	Jennifer R. Brown (Boston)
1:40 PM	2:00 PM	0:20	ABT199	William Wierda (Houston)
2:00 PM	2:50 PM	0:50	<b>Yohei Ito Memorial Lecture</b>	
			<i>Session Chair: Toshiaki Watanabe</i>	
2:00 PM	2:05 PM	0:05	Introduction: Yohei Ito Memorial Lecture	Toshiaki Watanabe (Tokyo)
2:05 PM	2:50 PM	0:45	Immune Checkpoint Blockade in Cancer Therapy: Prospects for Cures	Jim Allison (Houston)
2:50 PM	3:20 PM	0:30	<b>Break</b>	
3:20 PM	4:35 PM	1:15	<b>Checkpoint Inhibitors in Hematologic Malignancies</b>	
			<i>Session Chairs: Guillermo Garcia-Manero / Giovanni Martinelli</i>	
3:20 PM	3:35 PM	0:15	Hodgkin Lymphoma	Giovanni Martinelli (Bologna)
3:35 PM	3:50 PM	0:15	Non-Hodgkin Lymphoma	Jason Westin (Houston)
3:50 PM	4:05 PM	0:15	Myelodysplastic Syndromes	Guillermo Garcia-Manero (Houston)
4:05 PM	4:20 PM	0:15	Leukemia	Naval Daver (Houston)
4:20 PM	4:35 PM	0:15	Multiple Myeloma	Sagar Lonial (Atlanta)
4:35 PM	5:35 PM	1:00	<b>General IACRLRD Assembly</b>	
			by invitation only for IACRLRD members	
6:30 PM	9:00 PM		<b>Faculty Speaker Dinner (Invitation Only)</b>	
<b>Total</b>		<b>9:35</b>		

## Wednesday, November 1, 2017

Start	End	Time	Topic	Speaker
8:00 AM	9:15 AM	1:15	<b>Molecular Targets and Drug Discovery</b>	
			<i>Session Chairs: Ken Anderson / Hartmut Döhner</i>	
8:00 AM	8:15 AM	0:15	Molecular Targets in MF and MPNs	Alessandro Vannucchi (Florence)
8:15 AM	8:30 AM	0:15	Molecular Targets in AML	Hartmut Döhner (Ulm)
8:30 AM	8:45 AM	0:15	Epigenetic Modulation in MDS and AML	Jean-Pierre Issa (Philadelphia)
8:45 AM	9:00 AM	0:15	Molecular Pathophysiology of Aggressive Lymphoma	Kieron Dunleavy (Bethesda)
9:00 AM	9:15 AM	0:15	Molecular Pathophysiology of Myeloma and Clinical Applications	Ken Anderson (Boston)
9:15 AM	9:45 AM	0:30	<b>Break</b>	
9:45 AM	10:45 AM	1:00	<b>Myeloproliferative Neoplasms</b>	
			<i>Session Chairs: Serge Verstovsek / John Mascarenhas</i>	
9:45 AM	10:05 AM	0:20	How I Treat Myelofibrosis	Francisco Cervantes (Barcelona)
10:05 AM	10:25 AM	0:20	How I Treat Polycythemia Vera	Serge Verstovsek (Houston)
10:25 AM	10:45 AM	0:20	New Therapeutic Approaches to MPN	John Mascarenhas (NY)
10:45 AM	12:25 PM	1:40	<b>Lymphoma</b>	
			<i>Session Chairs: Magnus Björkholm / Julie Vose</i>	
10:45 AM	11:05 AM	0:20	How Can We Use Population-Based Registers in Hematology? Studies Focused	Magnus Björkholm (Stockholm)
11:05 AM	11:25 AM	0:20	How I Treat Aggressive Non-Hodgkin Lymphoma	Julie Vose (Omaha)
11:25 AM	11:45 AM	0:20	Monoclonal Antibodies in Lymphoma	Nathan Fowler (Houston)
11:45 AM	12:05 PM	0:20	CAR T-Cell Therapy in Lymphoma	Sattva Neelapu (Houston)
12:05 PM	12:25 PM	0:20	New Lymphoma Agents in the Pipeline	Andrew D. Zelenetz (New York)
12:25 PM	1:00 PM	0:35	<b>Box Lunch: Frank Rauscher Memorial Lecture</b>	
			<i>Session Chair: Genevffa Franchini</i>	
12:25 PM	12:30 PM	0:05	Introduction: Frank Rauscher Memorial Lecture	Genevffa Franchini (Bethesda)
12:30 PM	1:00 PM	0:30	European Leukemia Net: Relevant Clinical Updates in Acute Myeloid Leukemia	Clara Bloomfield (Columbus)
1:00 PM	2:20 PM	1:20	<b>Multiple Myeloma</b>	
			<i>Session Chairs: Carol A. Huff / Sagar Lonial</i>	
1:00 PM	1:20 PM	0:20	Optimal Therapy for Newly Diagnosed Multiple Myeloma	Carol Ann Huff (Baltimore)
1:20 PM	1:40 PM	0:20	How I Treat Salvage Myeloma	Bart Barlogie (New York)
1:40 PM	2:00 PM	0:20	Monoclonal Antibodies in Multiple Myeloma	Sagar Lonial (Atlanta)
2:00 PM	2:20 PM	0:20	Novel Agents in Development for Myeloma	Gareth Morgan (Little Rock)
2:20 PM			<b>Adjourn</b>	
<b>Total</b>		<b>6:20</b>		